Use of purine derivatives for the manufacture of drugs for the treatment of mucoviscidosis and diseases related to a defect in the targeting of proteins in cells
Purine derivatives for use in the treatment of mucoviscidosis, characterized in that said derivatives are selected from 2- (R, S) - (1-ethyl-2-hydroxyethylamino) -6-benzylamino-9-isopropylpurine, 2- (R) - (1- ethyl-2-hydroxyethylamino) -6-benzylamino-9-isopropylpurine and 2- (S) - (1-ethyl-2-hydroxyethylamino) -6-benzylamino-9-isopropylpurine.Derivados de purinas para su utilización en el tratamiento de la mucoviscidosis, caracterizados por que dichos derivados se seleccionan de entre la 2-(R, S)-(1-etil-2-hidroxietilamino)-6-benzilamino-9- isopropilpurina, la 2-(R)-(1- etil-2-hidroxietilamino)-6-benzilamino-9-isopropilpurina y la 2-(S)-(1-etil-2-hidroxietilamino)-6-benzilamino-9- isopropilpurina.
